SELLAS Life Sciences Group Inc.(SLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLS SELLAS Life Sciences Group Inc.

Pre-Mkt 01-23 04:33:46 EST

4.51

-0.07

-1.53%

盘前4.51

+0.000.00%

04:22 EST

High4.84	Low4.45	Vol5.65M
Open4.62	D1 Closing4.58	Amplitude8.62%
Mkt Cap766.70M	Tradable Cap766.70M	Total Shares170.00M
T/O25.76M	T/O Rate3.32%	Tradable Shares170.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SLS","market":"US","secType":"STK","nameCN":"SELLAS Life Sciences Group Inc.","latestPrice":4.51,"timestamp":1769115600000,"preClose":4.58,"halted":0,"volume":5650269,"hourTrading":{"tag":"盘前","latestPrice":4.51,"preClose":4.51,"latestTime":"04:22 EST","volume":71,"amount":320.2600195,"timestamp":1769160129780,"change":0,"changeRate":0,"amplitude":0.002217},"delay":0,"changeRate":-0.015283842794759887,"floatShares":170000000,"shares":170000000,"eps":-0.281267,"marketStatus":"Pre-Mkt","change":-0.07,"latestTime":"01-23 04:33:46 EST","open":4.62,"high":4.84,"low":4.445,"amount":25763049.5913543,"amplitude":0.086245,"askPrice":4.93,"askSize":100,"bidPrice":4.46,"bidSize":34,"shortable":3,"etf":0,"ttmEps":-0.281267,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769178600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":4.51,"preHourTrading":{"tag":"盘前","latestPrice":4.51,"preClose":4.51,"latestTime":"04:22 EST","volume":71,"amount":320.2600195,"timestamp":1769160129780,"change":0,"changeRate":0,"amplitude":0.002217},"postHourTrading":{"tag":"盘后","latestPrice":4.53,"preClose":4.51,"latestTime":"19:59 EST","volume":149027,"amount":671981.695,"timestamp":1769129981679,"change":0.02,"changeRate":0.004435,"amplitude":0.006652},"volumeRatio":0.6423285454322343,"impliedVol":1.6075,"impliedVolPercentile":0.656},"requestUrl":"/m/hq/s/SLS","defaultTab":"news","newsList":[{"id":"2605200448","title":"Mixed options sentiment in Sellas Life Sciences with shares down 1.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605200448","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605200448?lang=en_us&edition=fundamental","pubTime":"2026-01-23 06:00","pubTimestamp":1769119218,"startTime":"0","endTime":"0","summary":"Mixed options sentiment in Sellas Life Sciences (SLS), with shares down 8c near $4.50. Options volume relatively light with 13k contracts traded an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mixed-options-sentiment-in-sellas-life-sciences-with-shares-down-1-75-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mixed-options-sentiment-in-sellas-life-sciences-with-shares-down-1-75-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SLS"],"gpt_icon":0},{"id":"2604153820","title":"Amentum announces successful rollout of SLS rocket, Orion spacecraft from VAB","url":"https://stock-news.laohu8.com/highlight/detail?id=2604153820","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604153820?lang=en_us&edition=fundamental","pubTime":"2026-01-20 03:50","pubTimestamp":1768852207,"startTime":"0","endTime":"0","summary":"Amentum (AMTM) announces the successful rollout of the Space Launch System, SLS, rocket and Orion spacecraft from the Vehicle Assembly Building, VA...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amentum-announces-successful-rollout-of-sls-rocket-orion-spacecraft-from-vab-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amentum-announces-successful-rollout-of-sls-rocket-orion-spacecraft-from-vab-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLS","BK4139","BK4123","AMTM"],"gpt_icon":0},{"id":"2603261971","title":"Sellas Life Sciences enters agreement with IMPACT-AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2603261971","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603261971?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:37","pubTimestamp":1768397823,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences (SLS) announced that it has entered into an agreement with IMPACT-AML, a European collaborative initiative dedicated to advanc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sellas-life-sciences-enters-agreement-with-impact-aml-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sellas-life-sciences-enters-agreement-with-impact-aml-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SLS"],"gpt_icon":0},{"id":"2603619609","title":"Sellas Life Sciences Partners with IMPACT-AML to Expand SLS009 Trials into Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2603619609","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603619609?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:30","pubTimestamp":1768397457,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences Group Inc. has entered into a collaboration with IMPACT-AML, a European initiative focused on advancing treatments for acute myeloid leukemia . Through this agreement, IMPACT-AML will conduct a clinical study of Sellas’ CDK9 inhibitor SLS009 in combination with azacitidine and venetoclax for newly diagnosed AML patients with high-risk features. The partnership enables Sellas to expand its clinical program into Europe, with U.S. patient enrollment expected to begin in the first quarter of 2026 and European enrollment anticipated in the second quarter of 2026, subject to regulatory approvals. This collaboration is expected to improve capital efficiency and broaden patient access as the SLS009 program advances.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDLbJ08Dj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SLS","IE00BKPKM429.USD","SG9999014005.SGD","LU2095319765.USD","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","NDAQ","BK4112","BK4585","SG9999014039.USD","LU2210150020.SGD","SG9999014021.USD","SG9999014013.SGD","LU0314104364.USD"],"gpt_icon":0},{"id":"2603619999","title":"Sellas Life Sciences Group Inc - Sls009 U.S. Enrollment Planned for Q1 2026, Europe Enrollment  Anticipated in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2603619999","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603619999?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:30","pubTimestamp":1768397400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nTUABY1QDD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2603570619","title":"Sellas Life Sciences Enters Agreement With Impact-Aml to Expand Sls009 Clinical Program Into Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2603570619","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603570619?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:30","pubTimestamp":1768397400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nTUABY1QDD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2603003619","title":"SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2603003619","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603003619?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:30","pubTimestamp":1768397400,"startTime":"0","endTime":"0","summary":"Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollmentU.S. enrollment evaluating SLS009 in combination with AZA/V","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/14/3218619/0/en/SELLAS-Life-Sciences-Enters-Agreement-with-IMPACT-AML-to-Expand-SLS009-Clinical-Program-into-Europe.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS"],"gpt_icon":0},{"id":"2601362156","title":"Sellas Life Sciences Raises $26.5 Million from Warrant Exercises","url":"https://stock-news.laohu8.com/highlight/detail?id=2601362156","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601362156?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:31","pubTimestamp":1767879077,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences Group Inc. announced that it has received approximately $26.5 million in proceeds from the exercise of common stock warrants following December 31, 2025. As of January 7, 2026, the company reported having 170,282,026 shares of common stock outstanding.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDLb5KtDN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2601197008","title":"A Look At SELLAS Life Sciences Group (SLS) Valuation As REGAL Phase 3 Trial Nears Final Event Trigger","url":"https://stock-news.laohu8.com/highlight/detail?id=2601197008","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601197008?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:19","pubTimestamp":1767709173,"startTime":"0","endTime":"0","summary":"REGAL trial event trigger draws attention to SELLAS Life Sciences Group\nSELLAS Life Sciences Group (SLS) is back in focus after its latest update on the Phase 3 REGAL trial in acute myeloid leukemia, with investors closely watching for the final overall survival event trigger.\nThe company reported that 72 of the 80 required events had occurred as of December 26, 2025. This means the final analysis for its GPS maintenance therapy study now depends on a small number of additional patient...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/a-look-at-sellas-life-sciences-group-sls-valuation-as-regal","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/a-look-at-sellas-life-sciences-group-sls-valuation-as-regal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7104","SLS","SLS.AU","BK4139"],"gpt_icon":0},{"id":"2601699885","title":"Social Buzz: Wallstreetbets Stocks Advance Premarket Monday; SELLAS Life Sciences Group, Chevron to Open Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2601699885","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601699885?lang=en_us&edition=fundamental","pubTime":"2026-01-05 19:47","pubTimestamp":1767613639,"startTime":"0","endTime":"0","summary":"The most-talked-about stocks in the Reddit subforum Wallstreetbets were advancing hours before Monday's opening bell.SELLAS Life Sciences Group  rose by 11% premarket, following a 15.4% rise from the previous session.Chevron  was up 7.8% in pre-bell activity, after closing Friday with a 2.3% increase. Shares of oil-related firms were up in recent premarket activity Monday after the US attacked Venezuela, abducted its president, and announced that American companies would invest to restore crude production in the South American country.Palantir Technologies  advanced by 3.9% in premarket hours, swinging from a 5.6% fall at Friday's close.Micron Technology  rose by 3.9% pre-bell, following a 0.5% increase from the previous session.Ondas Holdings  was up 1.8% pre-bell, after closing Friday with a 12.9% rise.Tesla  was up 1.7% premarket, swinging from a 2.6% decline at Friday's close.Nvidia  was 1.2% higher hours before market open, after a 1.3% rise from Friday's session.Nike  advanced by","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2247934214.USD","NVD2.UK","BK4554","LU0077335932.USD","LU2108987350.USD","LU2092627202.USD","IE0004445015.USD","LU0006306889.USD","LU2237438978.USD","LU0345768740.USD","LU1917777945.USD","BK4579","LU1934455277.USD","LU2097344357.USD","LU0158827781.USD","LU0823434583.USD","LU2756315318.SGD","LU2065171402.SGD","HK0000306701.USD","LU0511384066.AUD","LU0612318385.USD","IE00BYQQ9H92.USD","IE00B19Z9Z06.USD","LU2106854487.HKD","LU0187121727.USD","SNVD.UK","LU2065171311.SGD","IE00BJTD4V19.USD","SG9999015358.SGD","LU0444971666.USD","LU1839511570.USD","BK7104","LU0278409577.USD","LU0094547139.USD","NVDD","LU0943347566.SGD","LU2322448791.USD","LU2213496289.HKD","BK4551","BK4553","LU0289960550.SGD","LU0889565833.HKD","LU2129689605.HKD","LU1242518931.SGD","LU2471134952.CNY","LU0342679015.USD","LU1989772840.SGD","LU1935042488.USD","LU2125154778.USD","LU0210536198.USD","SLS","LU0964807845.USD","LU1261432733.SGD","IE0034235295.USD","LU1674673428.USD","LU1989772923.USD","LU2357305700.SGD","IE00B5949003.HKD","LU0106261372.USD","BK4598","SG9999014898.SGD","LU2168564149.EUR","SG9999014906.USD","LU0128525929.USD","LU2294711713.HKD","LU0823421333.USD","IE000YTNTUN2.SGD","LU2360107168.USD","IE00BQXX3F31.USD","LU0456854461.SGD","LU1127390331.HKD","LU0256863902.USD","LU0234570918.USD","LU2592432038.USD","LU0630314457.HKD","LU1548497426.USD","LU1868837300.USD","IE00BDRTCR15.USD","LU0289961442.SGD","IE00B3SWFQ91.USD","LU0053666078.USD","IE0003U64NQ7.SGD","NVDU","LU2125154935.USD","LU2360106780.USD","LU1951200564.SGD","LU1868836914.USD","LU2249611893.SGD","SGXZ31699556.SGD","LU1791710582.SGD","LU0528227936.USD","BK4613","IE0034235303.USD","LU0345781412.USD","LU1267930813.SGD","LU2098885051.SGD","BK4146","NVD","IE00B4YYXB79.USD","LU0354030511.USD","SG9999017495.SGD","BK4512","LU2458330243.SGD","LU1804176565.USD","BK4533","IE00BWXC8680.SGD","LU2491050154.USD","LU0476273544.USD","LU2361044949.HKD","LU1989764748.USD","BK4614","LU0965509010.AUD","SG9999004303.SGD","LU2413666699.HKD","LU1066051225.USD","IE00B2Q91V27.USD","LU0070217475.USD","IE00B1BXHZ80.USD","IE00BFSS8Q28.SGD","LU0210528500.USD","LU1366192091.USD","LU2125909593.SGD","LU1861558580.USD","IE00BZ199S13.USD","LU0345769128.USD","LU2271345857.HKD","IE00BK4W5M84.HKD","LU2458330169.SGD","LU2931357623.SGD","LU2456880835.USD","LU0345780950.USD","IE00BQXX3C00.GBP","LU0708995401.HKD","SG9999000418.SGD","SG9999015341.SGD","LU0256863811.USD","SG9999002224.SGD","LU0320765646.SGD","SG9999014567.USD","LU0708994859.HKD","LU0787776722.HKD","LU1242518857.USD","LU1974910355.USD","BK4608","BK4548","LU0788109394.HKD","LU2361044865.SGD","BK4020","LU0070302665.USD","LU0225283273.USD","LU0345770993.USD","LU1934455863.HKD","LU2264538146.SGD","IE00BD6J9T35.USD","LU1633808545.USD","LU1923622291.USD","LU2552382215.SGD","LU1435385759.SGD","LU0320765059.SGD","SG9999014542.SGD","LU1988902786.USD","BK4559","LU0689472784.USD","LU2244417387.USD","LU1699723380.USD","LU0724617625.USD","BK4534","IE0004445239.USD","LU1066051811.HKD","LU2491050071.SGD","LU2602419157.SGD","BK4141","IE00BQXX3D17.EUR","LU2087621335.USD","IE0004086264.USD","LU0048584097.USD","LU2326559502.SGD","LU1430597077.USD","LU0203347892.USD","LU2746668974.SGD","IE000M9KFDE8.USD","IE00BYXW3230.USD","LU2211815571.USD","LU1720051108.HKD","LU1037948541.HKD","LU0820561818.USD","LU0080751232.USD","LU2242650005.HKD","LU0345769631.USD","IE00BZ1G4Q59.USD","IE00BKPKM429.USD","LU1861220033.SGD","LU1791710400.SGD","IE00B7SZLL34.SGD","LU0965508806.USD","LU1951198990.SGD","LU1868837136.USD","CVX","LU0310800379.SGD","LU1934455194.USD","LU2491049909.HKD","NVIW.SI","LU2065169927.USD","LU2860962120.EUR","LU0345770308.USD","LU0158827948.USD","LU2250418816.HKD","BK4604","NVDY","LU1992135399.USD","BK4588","LU0069063385.USD","LU0079474960.USD","LU1116320737.USD","LU2452424414.USD","LU2286300806.USD","IE00B1XK9C88.USD","IE00BGHQF524.EUR","LU0265550946.USD","LU1084165304.USD","LU2462157665.USD","LU2360032135.SGD","LU2077746001.SGD","LU0466842654.USD","LU2461242641.AUD","LU1674673691.USD","LU0308772762.SGD","LU1303367103.USD","LU2471134523.USD","LU1551013425.SGD","SGXZ23171101.USD","LU2265009873.SGD","BK4567","LU2471134796.USD","LU0097036916.USD","LU1623119135.USD","LU0122376428.USD","LU0985320562.USD","LU1366333091.USD","LU1935043536.SGD","IE00BJTD4N35.SGD","LU0211328371.USD","LU2129689514.USD","LU0274383776.USD","LU0823414478.USD","LU0208291251.USD","LU1712237335.SGD","SG9999018865.SGD","IE00B4JS1V06.HKD","LU2168563687.JPY","IE00BSNM7G36.USD","IE00BZ9MQY76.HKD","LU1145028129.USD","LU2242649171.HKD","LU1066053197.SGD","LU0061475181.USD","SG9999015952.SGD","LU0029864427.USD","LU1069344957.HKD","LU1429558221.USD","LU2097344431.USD","LU1066051498.USD","LU1244550494.USD","BK4555","LU1116320901.HKD","LU0942090050.USD","LU0612318971.USD","IE00BN29S564.USD","LU2023250330.USD","IE0001KFT4U8.USD","LU1935042215.USD","LU0823411888.USD","LU0072462426.USD","LU2272731782.SGD","LU0472753341.HKD","BK4139","SG9999014914.USD","BK4201","LU0316494557.USD","IE00BDCRKT87.USD","SG9999014575.USD","LU0300736062.USD","LU1267930573.SGD","IE00BKDWB100.SGD","LU1868836591.USD","IE00B19Z8X17.USD","LU2083900584.USD","BK4603","LU0345768153.USD","LU1035775433.USD","LU1815336760.USD","LU2092937148.SGD","BK4503","LU2237957902.USD","3NVD.UK","LU2063271972.USD","LU2237957811.SGD","IE00B3CCJ963.GBP","LU2471134879.HKD","LU2543165471.USD","SG9999015945.SGD","BK4532","LU0096362180.USD","LU0107464264.USD","LU1861215975.USD","LU2750360997.AUD","LU0965509101.SGD","LU1037948897.HKD","LU1629891620.HKD","LU2125909247.SGD","LU1821325948.USD","LU0198837287.USD","LU0689626769.HKD","LU1064131342.USD","LU2420271590.USD","LU0238689110.USD","LU0266013472.USD","LU1551013342.USD","NVD3.UK","LU0265550359.USD","IE00BHPRN162.USD","LU0154236417.USD","LU1868836757.USD","LU0640476718.USD","IE00BFSS7M15.SGD","IE00B775H168.HKD","LU2430703178.SGD","IE00B894F039.SGD","BK4561","LU0170899867.USD","BK4550","LU2746668461.USD","LU2023250504.SGD","LU0823414551.USD","LU2433249047.HKD","LU0823421416.USD","LU1267930730.SGD","LU1923622614.USD","LU0203345920.USD","LU1803068979.SGD","BK4570","LU2430703251.USD","LU0417517546.SGD","SG9999018857.SGD","IE00B3M56506.USD","LU1935043023.USD","LU0820562030.AUD","BK4527","SG9999015978.USD","IE00B19Z9505.USD","IE000W1ABFV2.USD","LU2168564065.EUR","LU0081259029.USD","LU1267930490.SGD","LU0353189763.USD","LU0882574139.USD","LU0957808578.USD","LU1074936037.SGD","IE00BFXG0V08.USD","HK0000320264.USD","LU0642271901.SGD","LU0390134368.USD","LU1852331112.SGD","LU0210533765.USD","LU2087625088.SGD","GB00BDT5M118.USD","LU1323610961.USD","LU0823434740.USD","LU1935042991.SGD","LU2272731600.USD","LU2089284900.SGD","LU2357125470.USD","LU2089283258.USD","SGXZ99366536.SGD","LU0889566641.SGD","LU0354030438.USD","LU0276348264.USD","2NVD.UK","LU0056508442.USD","IE00B19Z8W00.USD","LU1914381329.SGD","LU2129689431.USD","BK4605","LU0057025933.USD","LU2023251221.USD","LU1718418525.SGD","LU1778281490.HKD","LU0557290698.USD","LU2361045086.USD","LU2089985449.USD","IE00BK4W5L77.USD","LU1119994496.HKD","LU2750360641.GBP","LU0965509283.SGD","BK4592","LU0861579265.USD","LU0251132253.USD","LU0215105999.USD","LU0979878070.USD","LU2168564222.USD","BK4099","LU2322448957.HKD","IE0002270589.USD","LU1642822529.SGD","IE00BJJMRY28.SGD","LU2896262040.SGD","LU2756315664.SGD","IE00BMPRXN33.USD","LU2168564495.EUR","IE00B19Z3B42.SGD","LU0157215616.USD","LU0348723411.USD","LU2191332357.HKD","LU0868494617.USD","IE0004091025.USD","LU2290526834.HKD","LU0082616367.USD","BK4587","LU0672654240.SGD","IE0005OL40V9.USD","LU0347712357.USD","BK4023","LU1720051017.SGD","LU0444973449.USD","LU1280957306.USD","IE00B7KXQ091.USD","LU2028103732.USD","LU1316542783.SGD","LU0061474705.USD","IE00B19Z9P08.USD","LU1983260115.SGD","LU2473716301.USD","IE00B19Z3581.USD","LU1691799644.USD","IE00BJJMRX11.SGD","BK4547","LU0683600562.USD","BK4566","IE0034235188.USD","BK4581","BK4516","BK4529","LU1496350502.SGD","BK4575","LU1571399168.USD","BK4549","LU0320765489.SGD","LU2236285917.USD","LU0096364046.USD","LU0957791311.USD","IE00BMPRXR70.SGD","LU0203202063.USD","SGXZ51526630.SGD","LU0109392836.USD","NVDS.UK","LU1496350171.SGD","LU1861127337.USD","LU0786609619.USD","LU2048586759.USD","LU2111349929.HKD","LU2403377893.USD","LU2505996681.GBP","LU1989764664.SGD","LU1814569148.SGD","IE00BMPRXQ63.HKD","LU1815333072.USD","LU0788109477.HKD","LU1162221912.USD","LU1992135472.HKD","LU0792757196.USD","LU1861559042.SGD","LU0719512351.SGD","LU0300736492.USD","LU2505996509.AUD","LU2065170008.USD","LU2125909759.SGD","IE000KEQY171.SGD","LU0323591593.USD","LU2381873111.SGD","SG9999001424.SGD","SGXZ81514606.USD","BK4612","LU2413666426.HKD","IE0009G5SDU7.USD","LU0266512127.USD","LU1929549753.HKD","LU1923623000.USD","LU0310799852.SGD","LU0061474960.USD","SG9999015986.USD","LU0368265418.SGD","LU0124676726.USD","LU2054465674.USD","LU0127658192.USD","LU0109391861.USD","LU1232071149.USD","LU1721428933.USD","LU2463028550.USD","LU2487616109.SGD","SG9999002521.SGD","LU0211327993.USD","LU0494093205.USD","IE00BKVL7J92.USD","LU0868494708.USD","BK4543","LU0353189680.USD","BK4574","LU1244550221.USD","LU2417539215.USD","IE00BJLML261.HKD","LU2430703095.HKD","NVDX","LU0175139822.USD","IE0009356076.USD","NVDS","LU2125909916.SGD","LU0203201768.USD","BK4585","LU2133065610.SGD","LU0654597011.USD","LU2552382058.USD","TSYW.SI","BK4558","LU2552382132.HKD","SG9999014880.SGD","BK4511","LU0098860793.USD","SG9999014559.SGD","SG9999002232.USD","LU0267386448.USD","LU2506951792.HKD","LU1244550577.SGD","LU0289739343.SGD","LU2272731865.HKD","LU0234572021.USD","HK0000306685.HKD","HK0000320223.HKD","IE000ITXATA3.USD","LU0820561909.HKD"],"gpt_icon":1},{"id":"2595758618","title":"SELLAS Life Sciences Stock Is Surging Higher: What's Going On?","url":"https://stock-news.laohu8.com/highlight/detail?id=2595758618","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595758618?lang=en_us&edition=fundamental","pubTime":"2025-12-30 04:40","pubTimestamp":1767040800,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Group climbs higher after a premarket drop, reversing course as investors seem to react to new trial‑related updates.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/29/Stock-Market-Trading-Graph-And-Financial_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/29/Stock-Market-Trading-Graph-And-Financial_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49619904/sellas-life-sciences-stock-is-surging-higher-whats-going-on","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49619904/sellas-life-sciences-stock-is-surging-higher-whats-going-on","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","SLS"],"gpt_icon":0},{"id":"2595737669","title":"SELLAS Life Sciences Group Up Nearly 17%, on Track for Highest Close Since February 2023 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2595737669","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595737669?lang=en_us&edition=fundamental","pubTime":"2025-12-30 02:57","pubTimestamp":1767034620,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Group, Inc.  is currently at $3.36, up $0.49 or 16.9%. --Would be highest close since Feb. 23, 2023, when it closed at $3.69. --On pace for largest percent increase since Jan. 31, 2025, when it rose 21.8%. --Currently up seven consecutive days; up 59% over this period. --Longest winning streak since Dec. 16, 2025, when it rose for seven straight trading days. --Up 107.1% month-to-date; on pace for best month since Oct. 2022, when it rose 131.68%. --Up 222.6% year-to-date; on pace for best year since 2013, when it rose 224.18%. --Down 100% from its all-time closing high of $335363.30 on March 13, 2008. --Up 237.83% from 52 weeks ago , when it closed at $0.99. --Traded as high as $3.40; highest intraday level since Feb. 23, 2023, when it hit $3.85","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS"],"gpt_icon":0},{"id":"2595735394","title":"Sellas Life Sciences Says 72 Deaths Have Occurred in Phase 3 Acute Myeloid Leukemia Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2595735394","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595735394?lang=en_us&edition=fundamental","pubTime":"2025-12-29 22:15","pubTimestamp":1767017753,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences  said Monday it was informed that 72 deaths have occurred in its phase 3 Regal trial, currently evaluating its Galinpepimut-S therapy candidate in patients with acute myeloid leukemia after second complete remission.The company said that the Regal trial is an overall survival study, and a final analysis will be undertaken only after 80 deaths have been registered, which was previously expected to occur by the end of the year.Sellas said it remains blinded to all efficacy and survival data outcomes of the trial and will announce the 80th death event when it occurs.Shares of the company were down 6% in recent Monday premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLS","BK7104","BK4139","SLS.AU"],"gpt_icon":0},{"id":"2595738497","title":"Sellas Life Sciences Reports Progress in Phase 3 REGAL Trial of Galinpepimut-S for AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2595738497","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595738497?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:35","pubTimestamp":1767015311,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences Group Inc. announced an update on its ongoing Phase 3 REGAL trial evaluating Galinpepimut-S  as a potential maintenance therapy in patients with acute myeloid leukemia  following second complete remission. As of December 26, 2025, 72 events have occurred in the study, according to the contract research organization managing the trial. The company remains blinded to all efficacy and survival outcomes, and no analyses have been performed. The final analysis will be conducted once the 80th event occurs, at which time results will be announced. Results from the trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL4KzXmz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014021.USD","SG9999014039.USD","LU2095319765.USD","SG9999014013.SGD","LU2210149790.SGD","BK4112","NDAQ","IE00B64PRP62.GBP","LU2210150020.SGD","BK4585","BK4588","SLS","LU0314104364.USD","SG9999014005.SGD","IE00BGHQF748.EUR","BK4139"],"gpt_icon":0},{"id":"2595462738","title":"Sellas Life Sciences Provides Update on Pivotal Phase 3 Regal Trial of Galinpepimut-S (Gps) in Acute Myeloid Leukemia (Aml)","url":"https://stock-news.laohu8.com/highlight/detail?id=2595462738","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595462738?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:35","pubTimestamp":1767015300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nTUA9ZJ3KN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLS"],"gpt_icon":0},{"id":"1166741806","title":"New NASA Chief Vows: Moon Return Within Trump's Term","url":"https://stock-news.laohu8.com/highlight/detail?id=1166741806","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166741806?lang=en_us&edition=fundamental","pubTime":"2025-12-28 08:00","pubTimestamp":1766880038,"startTime":"0","endTime":"0","summary":"The new Administrator of the National Aeronautics and Space Administration (NASA), Jared Isaacman, has stated that the United States will return to the moon during Trump's second term, which is...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS","UFO","DXYZ"],"gpt_icon":1},{"id":"1120522495","title":"Key Reasons Behind Jared Isaacman's Appointment as NASA Administrator and Analysis of the Athena Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1120522495","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120522495?lang=en_us&edition=fundamental","pubTime":"2025-12-21 15:11","pubTimestamp":1766301068,"startTime":"0","endTime":"0","summary":"The nomination of Jared Isaacman as NASA Administrator by former President Trump in November 2025, later confirmed by the Senate (67-30 vote), was driven by three key factors: his commercial space...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4528","UFO","BK4587","BK4588","SINA","BK4139","BK4551","BK4585","SLS","BK4023","AI","DXYZ","BK4543"],"gpt_icon":1},{"id":"2590533441","title":"SELLAS Life Sciences Group (SLS): Valuation Check After Positive Phase 2 Data for SLS009 in AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2590533441","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590533441?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:29","pubTimestamp":1765373348,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Group (SLS) is back on traders radar after announcing positive Phase 2 data for SLS009 in combination therapy for tough to treat acute myeloid leukemia patients with myelodysplastic changes.\nSee our latest analysis for SELLAS Life Sciences Group.\nThe upbeat Phase 2 readout has added fresh fuel to a stock that was already in motion, with a 1 day share price return of 4.40 percent and year to date share price return of 77.57 percent. The 1 year total shareholder return of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-group-sls-valuation-check-after-positiv","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-group-sls-valuation-check-after-positiv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLS.AU","BK7104","SLS","BK4139"],"gpt_icon":0},{"id":"2589362143","title":"Sellas Life Says Phase 2 Study of Cancer Combination Treatment Shows 'Clinically Meaningful' Activity; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2589362143","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589362143?lang=en_us&edition=fundamental","pubTime":"2025-12-08 17:45","pubTimestamp":1765187112,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences Group  said Sunday that results of an ongoing phase 2 study of SLS009 in combination with azacitidine and venetoclax showed \"clinically meaningful\" activity in patients with relapsed or refractory acute myeloid leukemia, a type of cancer.Among the 35 evaluable patients, the overall response rate was 46%. Patients harboring ASXL1 or TP53 mutations achieved response rates of 48% and 57%, respectively. The company said the median overall survival was \"exceedingly higher\" than the expected 2.6 months in this patient population.The results didn't show any dose-limiting toxicities or treatment-related deaths, and the combination was well tolerated, according to Sellas.The company's shares were up 8.1% in recent premarket activity Monday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLS","BK7104","SLS.AU","BK4139"],"gpt_icon":0},{"id":"2589809491","title":"Sellas Life Sciences Announces Positive Phase 2 Results for SLS009 Combination in Relapsed AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2589809491","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589809491?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:00","pubTimestamp":1765148413,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences Group Inc. announced positive results from its ongoing Phase 2 study evaluating SLS009, a selective CDK9 inhibitor, in combination with azacitidine  and venetoclax  for patients with relapsed or refractory acute myeloid leukemia with myelodysplastic syndrome-related changes  following prior VEN-based treatment. The results, presented at the 67th American Society of Hematology  Annual Meeting in December 2025, showed a 46% overall response rate across all cohorts and a 58% overall response rate in patients with one prior line of therapy. The combination was reported to be safe and feasible, with no dose-limiting toxicities observed. The company plans to expand the study to evaluate SLS009 plus AZA/VEN in newly diagnosed AML with high-risk features in the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conten","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL8SKKlH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4139","BK4112","IE00BGHQF748.EUR","NDAQ","BK4585","LU2210150020.SGD","SG9999014005.SGD","BK4588","SLS","LU2210149790.SGD","LU0314104364.USD","SG9999014021.USD","IE00B3QW5Z07.USD","LU2095319765.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sellaslifesciences.com","stockEarnings":[{"period":"1week","weight":0.1745},{"period":"1month","weight":0.6282},{"period":"3month","weight":1.2663},{"period":"6month","weight":1.5056},{"period":"1year","weight":2.9561},{"period":"ytd","weight":0.1963}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0173},{"period":"6month","weight":0.0814},{"period":"1year","weight":0.1361},{"period":"ytd","weight":0.0104}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.014279},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.042394},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.053487},{"month":4,"riseRate":0.454545,"avgChangeRate":0.091111},{"month":5,"riseRate":0.727273,"avgChangeRate":0.118591},{"month":6,"riseRate":0.272727,"avgChangeRate":-0.198756},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.033023},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.058558},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.031827},{"month":10,"riseRate":0.363636,"avgChangeRate":0.051142},{"month":11,"riseRate":0.25,"avgChangeRate":-0.061889},{"month":12,"riseRate":0.25,"avgChangeRate":0.046982}],"exchange":"NASDAQ","name":"SELLAS Life Sciences Group Inc.","nameEN":"SELLAS Life Sciences Group Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SELLAS Life Sciences Group Inc.(SLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SELLAS Life Sciences Group Inc.(SLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SELLAS Life Sciences Group Inc.,SLS,SELLAS Life Sciences Group Inc.股票,SELLAS Life Sciences Group Inc.股票老虎,SELLAS Life Sciences Group Inc.股票老虎国际,SELLAS Life Sciences Group Inc.行情,SELLAS Life Sciences Group Inc.股票行情,SELLAS Life Sciences Group Inc.股价,SELLAS Life Sciences Group Inc.股市,SELLAS Life Sciences Group Inc.股票价格,SELLAS Life Sciences Group Inc.股票交易,SELLAS Life Sciences Group Inc.股票购买,SELLAS Life Sciences Group Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SELLAS Life Sciences Group Inc.(SLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SELLAS Life Sciences Group Inc.(SLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction